Literature DB >> 3186212

Therapeutic outcome of prednisone medication and of orbital irradiation in patients with Graves' ophthalmopathy.

W M Wiersinga1, T Smit, A L Schuster-Uittenhoeve, R van der Gaag, L Koornneef.   

Abstract

Response to treatment was evaluated prospectively in 58 patients with Graves' ophthalmopathy. Prednisone, administered to 44 patients, resulted in a favourable response in 29 patients (66%): excellent in 3, good in 10 and fair in 16 subjects; 15 patients (34%) did not respond. Orbital irradiation was administered to 39 patients of whom all except 4 had been treated previously with steroids. Six months later, 25 patients (64%) had responded favourably (excellent in 0, good in 9 and fair in 16 subjects) and 14 patients had not responded (36%). A favourable response to prednisone or irradiation was reflected in a general shift to lower grades in each of the classes 2-6 of the NOSPECS system. Responders were not different from non-responders with regard to age, sex, NOSPECS classification, ophthalmopathy index, interval between the onset of eye disease (or of thyroid disease if present) and the start of treatment, or the presence of thyroid disease. In conclusion, (1) the ratio of responders to non-responders is 2:1 for both prednisone treatment and orbital irradiation in Graves' ophthalmopathy, (2) the response is seen in all classes of the NOSPECS system, and (3) the response is not dependent on age, sex, severity or duration of eye disease, or the presence of thyroid disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3186212     DOI: 10.1159/000309924

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  9 in total

Review 1.  Pharmacological treatments for thyroid eye disease.

Authors:  Sara P Modjtahedi; Bobeck S Modjtahedi; Ahmad M Mansury; Dinesh Selva; Raymond S Douglas; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

3.  Effect of radiotherapy on moderate and severe thyroid associated ophthalmopathy: a double blind and self-controlled study.

Authors:  Yujie Wu; Boding Tong; Yongheng Luo; Guiyuan Xie; Wei Xiong
Journal:  Int J Clin Exp Med       Date:  2015-02-15

4.  Extraocular muscle surgery for Graves' ophthalmopathy: does prior treatment influence surgical outcome?

Authors:  M P Mourits; L Koorneef; A M van Mourik-Noordenbos; H M van der Meulen-Schot; M F Prummel; W M Wiersinga; A Berghout
Journal:  Br J Ophthalmol       Date:  1990-08       Impact factor: 4.638

5.  HLA-DR4 associated response to corticosteroids in Graves' ophthalmopathy patients.

Authors:  R van der Gaag; W M Wiersinga; L Koornneef; M P Mourits; M F Prummel; A Berghout; R R de Vries; G M Schreuder; J D'Amaro
Journal:  J Endocrinol Invest       Date:  1990-06       Impact factor: 4.256

6.  Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy.

Authors:  M F Prummel; W M Wiersinga; R Van der Gaag; M P Mourits; L Koornneef
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

7.  Clinical efficacy of combined rituximab treatment in a woman with severe Graves' ophthalmopathy.

Authors:  Xiaomei Liu; Hui Guo; Juan Liu; Bingyin Shi
Journal:  Exp Ther Med       Date:  2016-05-19       Impact factor: 2.447

8.  Compressive Optic Neuropathy and Repeat Orbital Decompression: A Case Series.

Authors:  Courtney Y Kauh; Shivani Gupta; Raymond S Douglas; Victor M Elner; Christine C Nelson; Leslie M Niziol; Alon Kahana
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2015 Sep-Oct       Impact factor: 1.746

9.  Outcome of thyroid associated ophthalmopathy treated by radiation therapy.

Authors:  Mirna Abboud; Asma Arabi; Ibrahim Salti; Fady Geara
Journal:  Radiat Oncol       Date:  2011-05-13       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.